Novel Glucagon/GLP-1 Receptor Dual Agonist Improved MASH in Phase II Study

Source link :

Survodutide, a novel glucagon/GLP-1 receptor dual agonist, improved metabolic dysfunction-associated steatohepatitis (MASH) with no worsening of fibrosis, according to results of a phase II trial. Among 293 patients with biopsy-confirmed MASH and F1 to F3 fibrosis, improvement in MASH with no worsening of fibrosis occurred in 47% of the patients in the 2.4-mg survodutide group, […]

Author : News Health

Publish date : 2024-06-07 20:15:51

Copyright for syndicated content belongs to the linked Source.